Robert Knerr - STADA Arzneimittel Executive

Executive

Robert Knerr is Member of the Management Board, Head of Business Development of STADA Arzneimittel Aktiengesellschaft since 2018.
Tenure 6 years
Phone49 6101 603 0
Webhttp://www.stada.de

STADA Arzneimittel Management Efficiency

The company has return on total asset (ROA) of 6.39 % which means that it generated a profit of $6.39 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on equity (ROE) of 22.55 %, meaning that it generated $22.55 on every $100 dollars invested by stockholders. STADA Arzneimittel's management efficiency ratios could be used to measure how well STADA Arzneimittel manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 1.73 B in total debt with debt to equity ratio (D/E) of 2.58, implying the company greatly relies on financing operations through barrowing. STADA Arzneimittel has a current ratio of 1.46, which is within standard range for the sector. Debt can assist STADA Arzneimittel until it has trouble settling it off, either with new capital or with free cash flow. So, STADA Arzneimittel's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like STADA Arzneimittel sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for STADA to invest in growth at high rates of return. When we think about STADA Arzneimittel's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Michael DroryCDW Corp
N/A
Reginald HedgebethSea
47
David StiresOlympic Steel
N/A
James PostOlympic Steel
N/A
Aletha NoonanCDW Corp
N/A
Steven OBrienCDW Corp
N/A
Sean HeenanOlympic Steel
43
Cassandra PowersOlympic Steel
N/A
Matthew GrussingOlympic Steel
N/A
Andrew WeberJohn Wiley Sons
N/A
Anand RaoCDW Corp
N/A
Michelle SPHROlympic Steel
N/A
Kevin MillerOlympic Steel
N/A
Guy BuckleySea
54
Michelle StephensDaily Journal Corp
N/A
Francis RuaneOlympic Steel
N/A
Roni CappadonnaSea
N/A
David ChenSea
N/A
Julie DillSea
55
Matthew DennisOlympic Steel
N/A
Sara GranackCDW Corp
N/A
STADA Arzneimittel Aktiengesellschaft engages in the health care and pharmaceuticals business worldwide. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare GmbH. Stada Arzneimi operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 123 people. STADA Arzneimittel Aktiengesellschaft [STDAF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

STADA Arzneimittel Leadership Team

Elected by the shareholders, the STADA Arzneimittel's board of directors comprises two types of representatives: STADA Arzneimittel inside directors who are chosen from within the company, and outside directors, selected externally and held independent of STADA. The board's role is to monitor STADA Arzneimittel's management team and ensure that shareholders' interests are well served. STADA Arzneimittel's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, STADA Arzneimittel's outside directors are responsible for providing unbiased perspectives on the board's policies.
Carl Oetker, Member of the Supervisory Board
JanNicolas Garbe, Member of the Supervisory Board
Dieter Koch, Member of the Supervisory Board
Eckhard Brueggemann, Member of the Supervisory Board
Mark Keatley, CFO, Member of the Executive Board
Ralph Grobecker, Managing Director of OTC segment
Martin Abend, Chairman of the Supervisory Board
Matthias Wiedenfels, Chief Bus. Devel. and Central Services Officer and Member of Executive Board
Arnold Hertzsch, Member of the Supervisory Board
Halil Duru, Member of the Supervisory Board
Tina Mueller, Member of the Supervisory Board
Engelbert Willink, Chairman of the Executive Board, CEO
Barthold Piening, Chief Technical Operations Officer, Member of the Executive Board
Steffen Wagner, Member of the Management Board, Head of Europe
Helmut Kraft, CFO and Member of Executive Board
Ute Pantke, Member of the Supervisory Board
Carsten Cron, Member of the Management Board, Head Emerging Markets
Frank Seiler, IR Contact Officer
Hartmut Retzlaff, Chairman of The Executive Board
Bernhard Duettmann, CFO
Miguel Pagan, Member of the Executive Board
Claudio Albrecht, Chairman of the Executive Board, CEO
Michael Siefke, Member of the Supervisory Board
Leslie Iltgen, Vice President Investor Relations
Eric Cornut, Member of the Supervisory Board
Peter Goldschmidt, Chairman of the Executive Board
Robert Knerr, Member of the Management Board, Head of Business Development
Jens Steegers, Member of the Supervisory Board
Birgit Kudlek, Member of the Supervisory Board
Guenter Au, Chairman of the Supervisory Board
Constantin Meyer, Member of the Supervisory Board
Rolf Hoffmann, Member of the Supervisory Board
Markus Metzger, Director of Investor Relations
Benjamin Kunstler, Member of the Supervisory Board
Gunnar Riemann, Member of the Supervisory Board
Bruno Schick, Member of the Supervisory Board

STADA Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is STADA Arzneimittel a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the STADA Arzneimittel information on this page should be used as a complementary analysis to other STADA Arzneimittel's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in STADA OTC Stock

If you are still planning to invest in STADA Arzneimittel check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the STADA Arzneimittel's history and understand the potential risks before investing.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Stocks Directory
Find actively traded stocks across global markets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Transaction History
View history of all your transactions and understand their impact on performance
Global Correlations
Find global opportunities by holding instruments from different markets
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities